WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed

Affiliations

¹ The Francis Crick Institute, London NW1 1AT, UK.
² Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
³ The Francis Crick Institute, London NW1 1AT, UK; Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
⁴ National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
⁵ National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK; University College London, London, UK.
⁶ The Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
⁷ The Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
⁸ The Francis Crick Institute, London NW1 1AT, UK. Electronic address: david.bauer@crick.ac.uk.

Mary Y Wu et al. Lancet. 2022.

. 2022 Dec 17;400(10369):2193-2196.

doi: 10.1016/S0140-6736(22)01938-9. Epub 2022 Oct 6.

¹ The Francis Crick Institute, London NW1 1AT, UK.
² Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
³ The Francis Crick Institute, London NW1 1AT, UK; Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
⁴ National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
⁵ National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK; University College London, London, UK.
⁶ The Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
⁷ The Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
⁸ The Francis Crick Institute, London NW1 1AT, UK. Electronic address: david.bauer@crick.ac.uk.

No abstract available

Comment in

WHO Living Guidelines on antivirals for COVID-19 are evidence-based.
Owen A, Diaz JV, Guyatt G, Lamontagne F, Stegemann M, Vandvik PO, Agoritsas T. Owen A, et al. Lancet. 2022 Dec 17;400(10369):2196-2198. doi: 10.1016/S0140-6736(22)02306-6. Epub 2022 Nov 10. Lancet. 2022. PMID: 36372074 Free PMC article. No abstract available.

1. UK Government Cabinet Office COVID-19 response: living with COVID-19. May 6, 2022. https://www.gov.uk/government/publications/covid-19-response-living-with...
1. Zheng B, Green ACA, Tazare J, et al. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platform. bioRxiv. 2022 doi: 10.1101/2022.05.22.22275417. published online Sept 22. (preprint). - DOI - PMC - PubMed
1. WHO Therapeutics and COVID-19: living guideline. July 14, 2022. https://apps.who.int/iris/bitstream/handle/10665/359774/WHO-2019-nCoV-th... - PubMed
1. WHO Therapeutics and COVID-19: living guideline. Sept 16, 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.5 - PubMed
1. Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397:2331–2333. - PMC - PubMed